King Tigan approved
Executive Summary
King's antiemetic Tigan (trimethobenzamide) 300 mg will be the reference drug for all trimethobenzamide products following Dec. 13 NDA approval. Under an agreement with the FDA, King submitted a bioequivalence study to resolve outstanding issues (1"The Pink Sheet" Oct. 8, p. 35). King has agreed to send a "Dear Health Care Professional" letter to alert the healthcare community about the new 300 mg strength...